Clinical Trials Logo

Clinical Trial Summary

1. To evaluate expression levels of circANKRD36 in the development and progression of DN. 2. To investigate correlation between expression levels of circANKRD36 and stages of DN. 3. To investigate correlation between expression levels of circANKRD36 and pro-inflammatory cytokine (TNF-α and IL-6) in T2DM patients with CKD.


Clinical Trial Description

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders that's become a global health burden affecting 463 million people worldwide according to the International Diabetes Federation (IDF). Diabetic nephropathy(DN) is one of the most common secondary complications of DM and is becoming a major cause of morbidity and mortality among diabetic patients . DN is a microvascular complication occurring in approximately 20-40% of patients with T2DM . DN has been described as a glomerular disorder with the following phases: glomerular hyperfiltration, incipient nephropathy, microalbuminuria, overt proteinuria and end-stage renal disorder. Microalbuminuria is the gold standard for the early diagnosis of DN. However, many studies have suggested that it is inadequate and has some drawbacks. Recent novel biomarkers have been accepted for early diagnosis and progression of DN in patients with T2DM . Renal cells are capable of synthesizing pro-inflammatory cytokines such as tumor necrotic factor-alpha (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), these cytokines acting in a paracrine or autocrine manner that leading to the development and progression of several renal disorders .Circular RNAs are class of endogenous non coding RNAs and are associated with numerous diseases like T2DM. Circular ankyrin repeat domain 36 (circANKRD36) involved in T2DM and inflammation-associated pathways via interaction with miRNAs, including hsa-miR-3614-3p, hsa-miR-498, and hsa-miR-501-5p. The expression of circANKRD36 was upregulated in peripheral blood leucocytes and was correlated with chronic inflammation in T2DM. Therefore, circANKRD36 can be used as a potential biomarker for screening chronic inflammation in patients with T2DM. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05061459
Study type Observational
Source Assiut University
Contact Marwa Magdy Hamed Mohamed, Assistant lecturer
Phone 01005745012
Email [email protected]
Status Not yet recruiting
Phase
Start date October 2021
Completion date November 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04562025 - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy N/A
Not yet recruiting NCT03658317 - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy N/A
Recruiting NCT02501772 - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy N/A
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Completed NCT02251067 - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients Phase 2
Completed NCT02829177 - Microalbuminuria and Allopurinol in Type 1 Diabetes Phase 4
Completed NCT01440257 - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria Phase 2
Active, not recruiting NCT01273675 - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00317954 - Spironolactone in Diabetic Nephropathy Phase 4
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Completed NCT01935167 - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01673204 - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Phase 4
Completed NCT01726816 - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01458158 - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease N/A
Active, not recruiting NCT01476501 - Vitamin D Supplementation in Diabetic Nephropathy Phase 2
Completed NCT01447147 - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Phase 2
Completed NCT01003236 - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy Phase 2
Completed NCT00535925 - Nephropathy In Type 2 Diabetes and Cardio-renal Events Phase 4
Completed NCT00097955 - Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria Phase 2